The first patient has been dosed in Protagonist Therapeutics’ Phase 2 clinical trial of PTG-200 for the treatment of moderate to severe Crohn's disease, the company announced. Still recruiting at 99 sites around the world, the randomized, placebo-controlled PRISM trial (NCT04102111) is evaluating the efficacy of twice-daily dosing of PTG-200 in 90 patients with moderate to severe Crohn's disease. Protagonist Therapeutics and Janssen Research & Development are working together to develop PTG-200 through the completion of the proof-of concept-study. "We are pleased to be progressing PTG-200 in collaboration with Janssen in a Phase 2 study in patients with Crohn's disease," Dinesh V. Patel, PhD, Protagonist's president and CEO, said in a press release. PTG-200 is an interleukin-23 (IL-23) receptor (IL-23R) inhibitor, designed to block the IL-23 pathway, helping fight inflammation in patients with inflammatory bowel disease (IBD). IL-23 is an inflammatory compound called a cytokine that is secreted by immune cells and known to cause inflammation, particularly in the context of IBD. There are several available antibody treatments that target the IL-23 pathway in patients with IBD.